Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers
2-Way Pagers to Improve Schizophrenia Medication Adherence
1 other identifier
interventional
55
1 country
1
Brief Summary
This study will determine whether using a pager improves medication adherence in people with schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable schizophrenia
Started Apr 2006
Typical duration for not_applicable schizophrenia
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2006
CompletedFirst Submitted
Initial submission to the registry
October 23, 2006
CompletedFirst Posted
Study publicly available on registry
October 25, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2009
CompletedResults Posted
Study results publicly available
April 29, 2014
CompletedOctober 25, 2017
September 1, 2017
3.7 years
October 23, 2006
March 10, 2014
September 22, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percent of Prescribed Medication Taken as Assessed by the Medication Event Monitoring System (MEMS)
Estimated percent of prescribed medication taken during month 6 of the study was calculated using all available data sources (MEMS supplemented by subject interview and pill counts).
Measured at Month 6
Study Arms (2)
A
EXPERIMENTALParticipants will receive treatment as usual and a 2-way pager for 6 months
B
ACTIVE COMPARATORParticipants will receive treatment as usual
Interventions
Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
Eligibility Criteria
You may qualify if:
- Meets DSM-IV criteria for schizophrenia or schizoaffective disorder
- Admitted to the Zucker Hillside Hospital for exacerbation of illness
- Speaks English
You may not qualify if:
- Presence of severe visual or motor impairments
- Mental retardation
- Neurologic disorder that may impact functioning such as seizures or vascular, neoplastic, traumatic, or infectious disorders affecting the brain
- Prescribed a psychotropic drug in depot form
- After hospital discharge, a living or treatment situation that includes dispensing of full medication regimen
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Northwell Healthlead
- National Institute of Mental Health (NIMH)collaborator
Study Sites (1)
The Zucker Hillside Hospital
Glen Oaks, New York, 11004, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Delbert Robinson, M.D.
- Organization
- Feinstein Institute for Medical Research
Study Officials
- PRINCIPAL INVESTIGATOR
Delbert G. Robinson, MD
Northwell Health
Publication Agreements
- PI is Sponsor Employee
- Yes
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Psychiatry
Study Record Dates
First Submitted
October 23, 2006
First Posted
October 25, 2006
Study Start
April 1, 2006
Primary Completion
December 1, 2009
Study Completion
December 1, 2009
Last Updated
October 25, 2017
Results First Posted
April 29, 2014
Record last verified: 2017-09